These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19218427)

  • 1. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.
    Ben-Kasus T; Schechter B; Lavi S; Yarden Y; Sela M
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3294-9. PubMed ID: 19218427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.
    Emde A; Pradeep CR; Ferraro DA; Ben-Chetrit N; Sela M; Ribba B; Kam Z; Yarden Y
    Oncogene; 2011 Apr; 30(14):1631-42. PubMed ID: 21132012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
    Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
    Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
    Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP
    Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.
    Ram S; Kim D; Ober RJ; Ward ES
    MAbs; 2014; 6(5):1211-9. PubMed ID: 25517306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2.
    Szymanska M; Fosdahl AM; Nikolaysen F; Pedersen MW; Grandal MM; Stang E; Bertelsen V
    J Cell Mol Med; 2016 Oct; 20(10):1999-2011. PubMed ID: 27469139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
    Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
    Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
    Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
    Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.
    Hurwitz E; Stancovski I; Sela M; Yarden Y
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3353-7. PubMed ID: 7724565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
    Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
    Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on anti-HER monoclonal antibodies.
    Ranson M; Sliwkowski MX
    Oncology; 2002; 63 Suppl 1():17-24. PubMed ID: 12422051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.
    Kita Y; Tseng J; Horan T; Wen J; Philo J; Chang D; Ratzkin B; Pacifici R; Brankow D; Hu S; Luo Y; Wen D; Arakawa T; Nicolson M
    Biochem Biophys Res Commun; 1996 Sep; 226(1):59-69. PubMed ID: 8806592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors.
    Furuuchi K; Berezov A; Kumagai T; Greene MI
    J Immunol; 2007 Jan; 178(2):1021-9. PubMed ID: 17202365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.
    Yip YL; Ward RL
    Cancer Immunol Immunother; 2002 Jan; 50(11):569-87. PubMed ID: 11807621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.